To determine the durability of complete responses in patients with metastatic melanoma or renal cancer treated with highdose bolus interleukin-2 (IL-2) as well as the factors associated with the development of a complete response and the antigens mediating clinical responses.
Objective
To determine the durability of complete responses in patients with metastatic melanoma or renal cancer treated with highdose bolus interleukin-2 (IL-2) as well as the factors associated with the development of a complete response and the antigens mediating clinical responses.
Methods
A consecutive series of 409 patients with either metastatic melanoma or renal cancer who were treated with high-dose bolus IL-2 in the Surgery Branch, National Cancer Institute, between September 1985 and November 1996 have been analyzed with a median potential follow-up of 7.1 years. All patients were treated with 720,000 lU/kg administered by 15-minute intravenous infusions every 8 hours for up to 5 days as clinically tolerated per cycle. Two cycles constituted a treatment course. Tumor-infiltrating lymphocytes (TIL) from melanoma patients were used to clone the genes encoding the tumor antigens responsible for clinical responsiveness.
Results
Thirty-three of 409 (8.1 %) patients treated with high-dose bolus IL-2 achieved a complete response and 37 (9%) achieved a partial response. Complete regression was seen in 6.6% and 9.3% of patients with metastatic melanoma and renal cancer, respectively. Twenty-seven of these 33 completely responding patients (82%) remain in ongoing continuous complete response from 39 to more than 148 months from the onset of treatment. Tumor regressions were seen at virtually all organ sites. The absence of prior treatment with immunotherapy, the total dose of IL-2 administered, and the maximal rebound lymphocytosis after cessation of IL-2 correlated with achieving a complete response.
Expression cloning techniques have identified a series of tumor antigens that are recognized by TIL grown from resected melanomas. These antigens are mainly melanoma/ melanocyte differentiation antigens, although mutated intracellular proteins can also serve as antigens.
Conclusions
Treatment with high-dose bolus IL-2 mediates complete cancer regression in approximately 8% of patients with metastatic renal cancer and melanoma. The great majority of these patients will enter durable complete regressions and appear to be cured of their metastatic cancer. Thus, immunotherapy with high-dose bolus IL-2 should be considered as initial therapy for appropriately selected patients with metastatic melanoma and renal cell cancer. Identification of the tumor antigens mediating clinical response is opening new therapeutic possibilities for cancer treatment.
virtually all ultimately die of their disease. The recognition in the mid-1980s of interleukin-2 (IL-2) as an immune regulator provided an additional modality for the treatment for these patients, and partial and complete tumor regressions were seen in a subset of patients treated with intravenous IL-2.1,2
Long-term follow-up of these responding patients has not been reported. The occasional complete responses reported with the use of combination chemotherapy in patients with 307
metastatic melanoma or with the use of alpha-interferon in patients with renal cancer have generally not been durable, and consequently the durability of complete responses in patients responding to IL-2 has been questioned. In the Surgery Branch, NCI, we began treating patients with high-dose bolus recombinant IL-2 alone in September 1985. [3] [4] [5] Since that time, we have treated 409 patients with metastatic melanoma or renal cell cancer using the -same regimen. As of March 1998, these patients have a potential median follow-up of 7.1 years, and the longest complete responder has been followed for 12.4 years. This singleinstitution experience has provided us with the opportunity to assess the durability and possible curative potential of treatment with high-dose IL-2 in patients with these metastatic cancers.
Thirty-three of these patients (8.1%) have undergone a complete regression of all metastatic cancer. Of these 33 patients, 27 Patients who had received prior IL-2 or who had evidence of concomitant severe respiratory, cardiovascular, or renal disease were not accepted into these trials. Before entry into the protocol, all patients were evaluated with computed tomographic (CT) or magnetic resonance imaging scans of the brain, chest CT scans or full lung tomograms, abdominal CT scans, and radionuclide bone scans. Patients were not eligible for this protocol if they had evidence of central nervous system metastases. Except for the early patients entered into this protocol, all patients older than 50 years of age underwent either a stress electrocardiogram or a stress radionuclide ejection or thallium scan, and patients with evidence of ischemic heart disease or significant arrhythmias on these studies were excluded. Based on previous evaluations (which identified factors having a possible association with complete or partial response), variables were examined according to whether they were believed to be of primary interest in association with complete response, or merely those to be evaluated in an exploratory fashion. Factors considered to be of primary interest were limited to the following: total IL-2 administered, previous immunotherapy, minimum platelet count during therapy, and maximal lymphocyte count during treatment. Because these considerations restricted the main analyses to only four variables, only an adjustment taking four variables into consideration is needed to adjust for multiple comparisons. The method of Hochberg7 was selected because it correctly holds the overall significance level to 0.05 but is not as restrictive as a Bonferroni procedure, which would have required that every individual probability value (of four) be 0.05/4 or less (or 0.0125 or less) to indicate significance in view of the number of comparisons performed.
Treatment
In addition to the main variables of interest, additional variables were examined and considered to have only an exploratory, hypothesis-generating association. They are presented without adjustment: initial sites of disease, performance status, sex, race, prior radiation therapy, prior surgery, prior chemotherapy, prior hormonal therapy, nephrotoxicity, cardiotoxicity, neurotoxicity, infection, age, interval from diagnosis to treatment, creatinine (pretreatment, maximum, and difference between these two), lymphocyte count (pretreatment), platelet count (pretreatment), and percentage weight gain. All probability values are two-sided (P2).
Factors that resulted in univariate associations that were significant (P2 ' 0.10) were included in logistic regression analysis models. Logistic regression analysis was performed using PROC LOGISTIC of SAS (SAS Institute, Cary, NC) to identify whether a predictive relation exists between complete response and any of the variables identified to be at least moderately associated with complete response.8 The probability of remaining in complete remission as a function of time, as well as the probability of dying from disease, was determined by the Kaplan-Meier method.
Cloning of the Genes Encoding Melanoma Antigens Responsible for Cancer Regression
To identify the melanoma antigens that appeared to be responsible for cancer regression, tumor-infiltrating lymphocytes (TIL) were grown from resected melanomas, and TIL capable of selectively recognizing the autologous cancer in vitro were identified using techniques previously described.9"10. Selected TIL were administered to cancer patients along with IL-2 to identify the TIL populations that were associated with tumor regression in vivo. 1 l These TIL were then used to identify the genes encoding the tumor antigens recognized by the TIL.12 cDNA libraries were prepared from melanoma cell lines and used to transfect target lines bearing the appropriate class I restriction element. The transfectants were assayed for recognition by TIL previously shown to be associated with tumor regression in vivo. The genes capable of mediating regression by TIL after transfection were then sequenced, and the amino acid sequence of the encoded proteins was identified.'3"14 RESULTS 
Patient Characteristics
Between September 1985 and November 1996, 409 patients (182 with metastatic melanoma and 227 with metastatic renal cancer) received a total of 673 courses of therapy with high-dose bolus IL-2 in the Surgery Branch, NCI (Table 1) . Fifty-nine of these patients also received second cycles of (25) 31 (17) 14 (8) 147 (81) 29 (16) 6 (3) 2 (1) 177 (97) 48 (26) 29 (16) 1 (1) 66 (36) 97 (53) 37 (20) (12) renal cell cancer had a single metastatic lesion; all other 7 (3) 8 (2) 35 (16) 101 (25) patients had multiple metastases.
60 (26) 157 (38) The toxicities of treatment seen in these patients were 16 (7) 53 (13) similar to those seen with the use of high-dose IL-2 in many previous publications from our group. There were four treatment-related deaths; however, these deaths all occurred 21 experienced a complete in our early experience with IL-2 (among the first 69 pagression for an overall retients). There were no treatment-related deaths in the last the 409 total patients, 33 340 patients treated with high-dose IL-2 in this study. experienced a complete and 37 a partial response for an overall response rate of 17.1%.
The response durations are shown in Table 3 , with a median potential follow-up of 7.1 years. All patients who experienced a partial regression ultimately progressed; the median duration of partial response for patients with melanoma or renal cancer was 7 and 11 months, respectively. In contrast, of 33 patients who experienced a complete response, 27 have continuous ongoing complete responses at 39 to 148 months. Of the 12 completely responding patients with melanoma, 2 had recurrent disease at 16 and 12 Prognostic Factors Associated With Complete Response Analyses of four principal parameters, as well as a large number of exploratory patient demographic, pretreatment, and treatment-related factors, were performed to attempt to identify factors that might predict or be associated with complete response among patients treated with high-dose IL-2 alone. Of the four principal factors analyzed, three showed a statistically significant association with complete response when appropriately corrected for the number of factors analyzed (Table 6 ). Although 25% (101 of 409) of all patients had received prior immunotherapy, only 2% of the patients who received prior immunotherapy had complete responses (P2 < 0.05), strongly suggesting that patients who received prior immunotherapy were less likely to respond than patients who had not been so treated. This was the only pretreatment factor among the many analyzed that had any clear association with complete response in these patients (see Table 6 ).
Two principal treatment factors, however, also were associated with the tendency to achieve a complete response. The total amount of IL-2 administered in the first treatment course was significantly higher in patients achieving a complete response (P2 < 0.05). After the cessation of high-dose IL-2, most patients developed a rebound lymphocytosis approximately 2 to 5 days later. This maximal lymphocyte count was also significantly higher in patients experiencing a complete response than in all other patients (P2 < 0.05). Minimal platelet count was not associated with complete response (P2 = 0.67). None of the other treatment-related factors listed in Table 6 had a significant association with complete response in these 409 patients. Logistic regression analyses failed to identify any important set of variables that could reliably predict complete response. This is because of both the relatively small fraction of total patients who were complete responders (8.1%) and because of the limited number of parameters identified in the overall evaluation that were potentially associated with complete response.
Identification of the Genes Encoding Cancer Regression Antigens
Using expression cloning techniques, a series of genes have been identified that encoded antigens recognized by TIL that had previously been shown to be associated with tumor regression in vivo. Many of these genes have been previously described.' 3-23 A summary of the melanoma antigens recognized by TIL is shown in Table 7 . Genes have been identified that are restricted by HLA-A2, A24, and A3 1. Most of these genes represent normal nonmutated melanoma/melanocyte differentiation antigens, indicating that these melanoma patients have broken tolerance to these cell proteins. Two follow-up for all patients in this series was 7.1 years. This series, the largest single-institution experience with this agent, thus provides the opportunity to evaluate, with prolonged follow-up, a consistently treated series of patients with these two diagnoses.
Of 182 melanoma patients, 12 (6.6%) underwent a complete response, as did 21 of 227 (9.3%) patients with renal cell cancer. Of these 33 patients undergoing a complete response, only 6 have had recurrent disease. The remaining 27 patients (82%) have continuous ongoing complete regressions at more than 39 to more than 148 months from the onset of treatment; 25 of these patients have ongoing complete responses for more than 4 years and 15 for more than 7 years. As shown in Tables 4 and 5 , most patients had multiple metastatic lesions, and tumor regressions were seen at sites throughout the body, including the lung, liver, lymph nodes, bone, and subcutaneous and cutaneous tissues. It thus appears that the great majority of patients with metastatic renal cell cancer or melanoma who undergo a complete response will experience a durable and perhaps curative tumor regression. Thirty-seven of the 409 patients in this series experienced an objective partial response; in 14 of these patients, the response lasted more than 1 year and in 5 patients more than 2 years, but all partial responders ultimately suffered recurrent disease.
Attempts were made to identify the characteristics of the subset of patients undergoing a complete response. An extensive analysis was performed of prognostic factors in patients treated with high-dose IL-2, comparing complete responders to all other patients. This revealed three parameters that correlated with complete response. Patients who had received prior immunotherapy with any modality other than IL-2 had a lower chance of experiencing a complete response (2 of 101; 2%) than did patients who had not previously received immunotherapy (31 of 307; 10.1%). It thus appeared that patients who underwent failed immune manipulations before IL-2 administration had an altered ability to respond effectively to treatment with high-dose bolus IL-2. The total amount of IL-2 administered also was significantly higher in complete responders. This corroborated animal data indicating a direct relation between the amount of IL-2 administered and antitumor responses. IL-2 causes a transient decrease of lymphocytes in the peripheral circulation, which then rebounds after IL-2 administration is stopped. The magnitude of this lymphocyte rebound was the third criterion studied that directly correlated with a tendency toward complete response. Thus, except for prior treatment with immunotherapy, there were no pretreatment factors among the many listed in Table 6 that could predict which patients were likely to experience a complete response when treated with high-dose bolus IL-2.
The or information on your patients while they are under treatment to demonstrate increased infiltration with lymphocytes or any change in the staining of those lymphocytes or in the activity of those lymphocytes to indicate that it is truly lymphocytic activation which is producing these responses? That seems like a simple, naive question, but I would like to know if you can confirm histologically that the response to IL-2 stimultes lymphocyte attack on the neoplasms.
The other question has to do with the illness produced by giving IL-2. You naturally didn't have time to go into that in detail. Several of your patients were in the intensive care ward while they were under treatment. I would like to know the nature of the response to IL-2. How sick does it make patients? And in what way does it make them sick?
Now, my suggestion is based on the fact that in the second half of this century, two new approaches to malignancy have been very encouraging. And they have both been pursued from their initial discovery to their present-day use by Fellows of this Association. One is the immunologic approach pursued by Dr. Rosenberg and several other of our colleagues. The other is based on neovascularization in tumors, an approach first described by Dr. Folkman, who is here this moming. I would just express the hope and the suggestion that Rosenberg and Folkman would study the two modalities together. A tumor which has been compromised by immunotherapy might be especially vulnerable to treatment directed toward its neovascularization. Such might be done with endostatin or somatostatin. Vice versa, a tumor that has had its vascular supply compromised might be very sensitive to immunological therapy. I hope they will get together and work out a combined approach. Thank you for a wonderful paper. Interleukin-2 administration is associated with toxicity. The earliest physiologic change we see is a decrease in systemic vascular resistance which can be associated with hypotension and tachycardia. We have learned to effectively control these side effects. In the first 157 patients tested we had four treatmentrelated deaths but, recently we have treated over 800 consecutive patients with no treatment related mortality. I believe treatment with high-dose IL-2 can be administered safely by those with ex~perience, certainly as safely as most combination chemotherapies in common use.
